Biological and molecular properties of a new αvβ3/αvβ5 integrin antagonist

被引:69
作者
Belvisi, L
Riccioni, T
Marcellini, M
Vesci, L
Chiarucci, I
Efrati, D
Potenza, D
Scolastico, C
Manzoni, L
Lombardo, K
Stasi, MA
Orlandi, A
Ciucci, A
Nico, B
Ribatti, D
Giannini, G
Presta, M
Carminati, P
Pisano, C
机构
[1] R&D Sigma Tau SpA, Area Oncol, I-00040 Monte Porzio Catone, Italy
[2] Univ Milan, Ctr Biomol Interdisciplinary Studies & Ind Applic, Organ & Ind Chem Dept, Milan, Italy
[3] CNR, Inst Mol Sci & Technol, I-20133 Milan, Italy
[4] Univ Roma Tor Vergata, Inst Pathol, I-00173 Rome, Italy
[5] Univ Bari, Sch Med, Dept Human Anat & Histol, Bari, Italy
[6] Univ Brescia, Sch Med, Dept Biomed Sci & Technol, Unit Gen Pathol & Immunol, Brescia, Italy
关键词
D O I
10.1158/1535-7163.MCT-05-0120
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the present study was to identify specific alpha(v)beta(3)/alpha(v)beta(5) integrin antagonists active on tumor-induced angiogenesis. To this purpose, in vitro integrin-binding assays were used to screen a library of conformationally constrained bicyclic lactam Arg-Gly-Asp -containing pseuclopeptides. The results identified ST1646 as a high-affinity specific ligand for alpha(v)beta(3) and alpha(v)beta(5) integrins with negligible interacting with alpha(5)beta(1) integrin. In all the assays, ST1646 was equipotent to or more potent than the well -characterized integrin antagonists c(RGDfV) and cyclo(Arg-Gly-Asp-D-Phe-[NMe]Val) (EMD121974). In the choriciallantoic membrane assay, topical administration of ST1646 was able to prevent the angiogenic responses elicited by recombinant fibroblast growth factor-2 or vascular endothelial growth factor. In addition, systemic administration of ST1646 in mice exerted a significant antiangiogenic activity on neovascularization triggered by mammary carcinoma MDA-MB435 cells implanted s.c. in a dorsal air sac via a (Millipore Filter Corporation, Bedford, MA) chamber. Moreover, ST1646 delivery via an osmotic pump inhibited the growth and vascularization of tumor xenografts originating from the injection of alpha(v)beta(3)/alpha(v)beta(5)-expressing human ovarian carcinoma cells in nude mice. In agreement with the biochemical and pharmacologic studies, Monte Carlo/Stochastic Dynamics simulation showed that the bicyclic scaffold in ST1646 forced the compound to assume a preferred conformation superimposable to the X-ray conformation Of alpha(v)beta(3)-bound EMD121974. Accordingly, computer-docking studies indicated that the ST1646-003 integrin complex maintains the ligand-receptor distances and interactions observed in the crystalline EMD121974-alpha(v)beta(3) integrin complex. Taken together, these observations indicate that ST1646 represents a dual alpha(v)beta(3)/alpha(v)beta(5) integrin antagonist with interesting biochemical and biological features to be tested in cancer therapy.
引用
收藏
页码:1670 / 1680
页数:11
相关论文
共 62 条
[1]  
Aplin AE, 1998, PHARMACOL REV, V50, P197
[2]   Coming to grips with integrin binding to ligands [J].
Arnaout, MA ;
Goodman, SL ;
Xiong, JP .
CURRENT OPINION IN CELL BIOLOGY, 2002, 14 (05) :641-651
[3]   Cyclic RGD peptides containing azabicycloalkane reverse-turn mimics [J].
Belvisi, L ;
Caporale, A ;
Colombo, M ;
Manzoni, L ;
Potenza, D ;
Scolastico, C ;
Castorina, M ;
Cati, M ;
Giannini, G ;
Pisano, C .
HELVETICA CHIMICA ACTA, 2002, 85 (12) :4353-4368
[4]   Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides [J].
Belvisi, L ;
Bernardi, A ;
Checchia, A ;
Manzoni, L ;
Potenza, D ;
Scolastico, C ;
Castorina, M ;
Cupelli, A ;
Giannini, G ;
Carminati, P ;
Pisano, C .
ORGANIC LETTERS, 2001, 3 (07) :1001-1004
[5]   Platelet-derived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β3 integrin through its extracellular domain [J].
Borges, E ;
Jan, YW ;
Ruoslahti, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (51) :39867-39873
[6]   AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL [J].
BORN, GVR .
NATURE, 1962, 194 (4832) :927-&
[7]   Integrins in invasive growth [J].
Brakebusch, C ;
Bouvard, D ;
Stanchi, F ;
Saki, T ;
Fässler, R .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (08) :999-1006
[8]   REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS [J].
BROOKS, PC ;
CLARK, RAF ;
CHERESH, DA .
SCIENCE, 1994, 264 (5158) :569-571
[9]   ANTIINTEGRIN ALPHA-V-BETA-3 BLOCKS HUMAN BREAST-CANCER GROWTH AND ANGIOGENESIS IN HUMAN SKIN [J].
BROOKS, PC ;
STROMBLAD, S ;
KLEMKE, R ;
VISSCHER, D ;
SARKAR, FH ;
CHERESH, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (04) :1815-1822
[10]   INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].
BROOKS, PC ;
MONTGOMERY, AMP ;
ROSENFELD, M ;
REISFELD, RA ;
HU, TH ;
KLIER, G ;
CHERESH, DA .
CELL, 1994, 79 (07) :1157-1164